Villejuif

• A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C … Ended recruitment
  2024-514032-25-00 4 2024-12-11 Patients with a histilogically confirmed diagnosis of cervical squamou
• L19IL2/L19TNF in skin cancer patients Ended recruitment
  2024-518531-10-00 4 2024-11-26 Phase II, open label, multicentric, proof-of-principle basket trial in
• Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended recruitment
  2023-508073-87-00 7 2024-11-14 Advance solid tumors harboring the KRAS G12C mutation
• PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first … Ended recruitment
  2024-518553-41-00 5 2024-11-08 colon cancer and rectal with liver metastasis
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer
• Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended recruitment
  2024-511202-23-00 4 2024-10-31 Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
• A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastat … Ended recruitment
  2023-509867-26-00 1 2024-10-14 Advanced/metastatic solid tumor
• A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep … Ended recruitment
  2023-506717-21-00 9 2024-10-02 Breast Cancer
• A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended recruitment
  2023-503714-77-00 4 2024-10-01 Advanced Non-Small Cell Lung Cancer
• JAK1 inhibitor treatment of inflammatory liver adenomas Ended recruitment
  2023-505278-13-00 4 2024-10-01 -women with an inflammatory HCA proven at histology and with at least
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Ra … Ended recruitment
  2022-502269-13-00 4 2024-09-24 Glioma
• AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous … Ended recruitment
  2024-511195-33-00 3 2024-09-23 Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• STUDY AGORA-1 / ALFA 2100: Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukem … Ended recruitment
  2023-504176-25-00 9 2024-08-08 Acute Myeloid Leukemia
• Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended recruitment
  2023-509633-39-00 7 2024-08-06 Advanced solid tumours
• Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma Ended recruitment
  2023-505177-32-00 4 2024-07-31 Intermediate-high -risk RCC, high-risk RCC who have undergone nephrect
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell … Ended recruitment
  2023-503594-38-00 1 2024-07-15 Select B-Cell malignancies.
• AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT … Ended recruitment
  2023-508130-33-00 9 2024-07-03 ADVANCED OR METASTATIC BREAST CANCER
• A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Ended recruitment
  2023-506228-10-00 7 2024-06-27 Pancreatic Ductal Adenocarcinoma
• Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Ended recruitment
  2023-509047-26-00 1 2024-06-13 Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer
• A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar … Ended recruitment
  2023-508459-37-00 1 2024-05-28 HER2-positive advanced solid tumours
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca … Ended recruitment
  2023-507995-33-00 9 2024-05-23 MSI-H/dMMR Gastric cancer
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended recruitment
  2022-501234-37-00 7 2024-05-07 Solid Tumours
• A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended recruitment
  2023-505658-17-00 4 2024-04-16 Muscle-invasive Urothelial Carcinoma

Showing 529–552 of 961 trials